WUXI BIOLOGICS Aktie

 

SUZHOU, China, May 26, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) located in Suzhou has received Good......

WUXI BIO (02269.HK) announced that, pursuant to the repurchase mandate, the company is authorized to repurchase up to 407 million shares on the Hong Kong Stock Exchange, representing 10% of the total number of issued shares as at the date of the annual general meeting.On May 24, the company resolved to utilize the repurchase man......

SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been......

Citi published a research report stating that results over the past fiscal year and the recent earnings season for 1Q have confirmed continued improvement in the fundamentals of Chinas healthcare sector, driven by innovative drugs and CDMOs (Contract Development and Manufacturing Organizations). Domestic medical technology, hea......

CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu,......

WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2),......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

SHANGHAI, April 17, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.......

Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April 14, 2026 /PRNewswire/ -- WuXi Biologics......

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has......

UBS research report indicated that WUXI BIO (02269.HK) met expectations with its performance in the second half of last year, with revenue increasing by 17.2% year-on-year to RMB11.8 billion (same below), and profit attributable to shareholders rising by 38.3% year-on-year to RMB2.6 billion. The gross profit margin improved by 5......

SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY;......

WUXI BIO (02269.HK) announced its full-year results for the year ended December 31, 2025. Revenue reached RMB21.79 billion, a YoY rise of 16.7%. It recorded net profit of RMB4.908 billion, a YoY hike of 46.3%, with an EPS of RMB1.22. Gross profit added by 30.9% YoY to RMB10.019 billion, and the gross profit margin improved by 5%......

SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact. WuXi Biologics has been named to the CDP......

SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma......

WILMINGTON, Del., March 12, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today......

SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in......

As AI technology continues to develop, investors are shifting their focus from "AI enabling industries" to "AI disintermediating middlemen", CLSA said in a research report. For CRO/ CDMO, AI is expected to have a clearer net positive for integrated CRDMO platforms. In contrast, the internal adoption of AI by ......